113 filings
Page 4 of 6
8-K
lu89wu1zdnxjwf
31 Jul 20
Submission of Matters to a Vote of Security Holders
8:43am
8-K
9m3vki
28 Jul 20
Novan President and CEO, Paula Brown Stafford Named Chairman of the Board
8:09am
8-K
49annc7zn7rq4dm
22 Jul 20
Entry into a Material Definitive Agreement
7:05am
8-K
ycem plofwr2yhcs
16 Jul 20
Termination of a Material Definitive Agreement
4:45pm
8-K
0ty3ue4gzoy
9 Jul 20
Other Events
4:45pm
8-K
rfhris7td7q sos9hee6
25 Jun 20
Novan Anticipates Current Cash Position Provides Sufficient Capital to Conduct Additional SB206 Phase 3 Pivotal Trial
8:07am
8-K
ypdyf jjypq6hd
16 Jun 20
Entry into a Material Definitive Agreement
9:44pm
8-K
c86sft05bg48nt
15 May 20
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
8:01am
8-K
sbzjeajf4td
23 Apr 20
Entry into a Material Definitive Agreement
4:49pm
8-K
ni68dvk72mz
3 Apr 20
Novan Receives Verbal Guidance from FDA for SB206 and Announces Sato Program Advancement
8:21am
8-K
gy69e6rsdqoj8 yk
26 Mar 20
Entry into a Material Definitive Agreement
4:16pm
8-K
jgbegx9tj azp9
23 Mar 20
Novan Announces Data from B-SIMPLE Week 24 Safety Evaluation and COVID-19 Business Updates
8:20am
8-K
lz2tl 5a2so8qg5aqk4h
3 Mar 20
Entry into a Material Definitive Agreement
4:18pm
8-K
swm8vu390sxkqt xtkix
6 Feb 20
Novan Provides SB206 Program and Business Update
8:36am
8-K
77zi3qbn zkkv9m
4 Feb 20
Departure of Directors or Certain Officers
4:17pm
8-K
gwiwbk7
3 Jan 20
Novan Reports Top-Line Efficacy Results from Phase 3 Trials of SB206 for Molluscum Contagiosum
8:13am
8-K
nghugoq8ld cwuyqv
18 Dec 19
Novan Announces Planned Chief Executive Officer Transition
8:05am
8-K
j6opm
5 Sep 19
Novan and Aspire Capital Enter into a Common Stock Purchase Agreement for up to $25 Million
6:36am
8-K
p60z32id9birqcd9ubw
6 Aug 19
Departure of Directors or Certain Officers
4:34pm
8-K
7o05mhzqgxd2i5ah
9 May 19
Novan Completes Funding Transaction with Ligand Pharmaceuticals
4:17pm